Literature DB >> 12476379

[Primary hip- and knee arthroplasty--comparison of the actual costs with the Australian diagnosis related groups (DRG)-].

N Schürmann1, R T Müller.   

Abstract

AIM: With the introduction of the Australian DRG system in Germany the question arises which current procedures remain reasonable in cost. The present study compares the actual costs with the expected DRG reimbursement. PATIENTS AND METHODS: Prospective analysis of 23 patients with primary hip and 26 with knee arthroplasty was performed to identify all cost factors during the hospitalization period including all applied measures. Retrospective analysis was carried out of the additional costs of relevant concomitant diseases (liver transplantation, haemophilia).
RESULTS: Expenses of 6231 euro; for hip and 6453 euro; for knee implants were covered by the DRG reimbursement. Although a special reimbursement was paid, the additional costs of the concomitant diseases resulted in a financial loss.
CONCLUSION: To cover the current costs for patients free of complications, an enormous reduction of the length of stay is required. Otherwise complicated cases may result in a loss of quality or selection of patients. The present cost analysis outlines a guideline for an individual calculation and assessment of the necessary DRG reimbursement.

Entities:  

Mesh:

Year:  2002        PMID: 12476379     DOI: 10.1055/s-2002-36093

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  2 in total

1.  [Economic impact of infected total hip arthroplasty in the German diagnosis-related groups system].

Authors:  M Haenle; C Skripitz; W Mittelmeier; R Skripitz
Journal:  Orthopade       Date:  2012-06       Impact factor: 1.087

2.  Surgical treatment approaches and reimbursement costs of surgical site infections post hip arthroplasty in Australia: a retrospective analysis.

Authors:  Katharina M D Merollini; Ross W Crawford; Nicholas Graves
Journal:  BMC Health Serv Res       Date:  2013-03-11       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.